PT-141 (Bremelanotide)
1–2 mg · As needed (max 1×/72h)
Evidence
- Human Studies
- 15
- Animal Studies
- 20
- Clinical Status
- FDA Approved
- Confidence
- Moderate
- Long-Term Safety
- Established for the approved indication and population; male off-label use has less formal long-term data
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A melanocortin receptor agonist (MC3R/MC4R) that acts centrally on the nervous system rather than on vascular pathways the way PDE5 inhibitors (e.g. sildenafil) do. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women; off-label male use is common but has less formal trial data specific to men.
Common Protocols
- 1–2 mg subcutaneous, roughly 45 minutes before activity, no more than about once every 72 hours per approved labeling
Side Effects
- Nausea (common, often dose-limiting)
- Flushing, headache
- Transient increase in blood pressure
Interactions
- Caution combining with other medications that affect blood pressure
Practical Details
- Cost
- $$
- Typical Vial Size
- 10 mg
- Storage
- Refrigerate after reconstitution
Research Links
Sexual function; use 45 min before